Atnaujinkite slapukų nuostatas

100 Questions & Answers About Cholangiocarcinoma, Gallbladder, and Bile Duct Cancers 2nd New edition [Minkštas viršelis]

4.33/5 (4 ratings by Goodreads)
,
  • Formatas: Paperback / softback, 200 pages, weight: 170 g
  • Išleidimo metai: 29-Nov-2021
  • Leidėjas: Jones and Bartlett Publishers, Inc
  • ISBN-10: 128424847X
  • ISBN-13: 9781284248470
Kitos knygos pagal šią temą:
100 Questions & Answers About Cholangiocarcinoma, Gallbladder, and Bile Duct Cancers 2nd New editionDidesnis paveikslėlis
  • Formatas: Paperback / softback, 200 pages, weight: 170 g
  • Išleidimo metai: 29-Nov-2021
  • Leidėjas: Jones and Bartlett Publishers, Inc
  • ISBN-10: 128424847X
  • ISBN-13: 9781284248470
Kitos knygos pagal šią temą:
Pastovi nuoroda: https://www.kriso.lt/db/9781284248470.html
Raktažodžiai:
Advocate For Your CareIt's expected that you will have questions about biliary cancer upon diagnosis. Whether it's your own diagnosis or a diagnosis of a loved one, this easy-to-read guide provides invaluable practical knowledge such as help for preparing to meet with an oncologist, seeking a second opinion, and understanding clinical trials. 100 Questions & Answers About Cholangiocarcinoma, Gallbladder, and Bile Duct Cancers is a resource that empowers patients and caregivers with the information needed to navigate their treatment with realistic goals for a good quality of life and targeted long-term survivorship. The perspective of patients and doctors is provided in this book with comprehensive answers to the most asked questions with added guidance for support and access to support services. You are the best solution to your cancer care.
Preface vii
Part One The Basics
1(10)
Questions 1-5 Cover Basic Information about biliary cancers, including
1 What is cancer?
2 What is bile and what are bile ducts?
3 What does the gallbladder do?
4 Are there different types of biliary cancers?
5 What is Next Generation Sequencing (NGS)?
Part Two Risk Factors
11(8)
Questions 6-11 Discusses risk factors for biliary cancers, including
6 How common is cholangiocarcinoma, and what are the risks for developing it?
7 Can cholangiocarcinoma occur along with liver cancer?
8 How common is extrahepatic bile duct cancer, and what are the risks of developing it?
9 How common is gallbladder cancer, and what are the risks of developing it?
10 Should I have genetic germline testing to assess my risk of developing biliary cancer?
11 Does my family need to be screened for biliary cancers? Should my family members have their gallbladders removed if I have gallbladder cancer?
Part Three Diagnosis and Staging
19(10)
Questions 12-20 Describes the diagnosis and staging of biliary cancers, including
12 What are the signs and symptoms of cholangiocarcinoma?
13 How is cholangiocarcinoma diagnosed?
14 What are the symptoms of extrahepatic bile duct cancer?
15 How is extrahepatic bile duct cancer diagnosed?
16 What are the symptoms of gallbladder cancer?
17 How is gallbladder cancer diagnosed?
18 What is a pathology report of a biopsy?
19 What is cancer staging, and why is it relevant?
20 How is staging performed?
Part Four Coping with the Diagnosis
29(10)
Questions 21-26 Discuss patients' support needs after a diagnosis of biliary cancers, including
21 How long do people with biliary cancer live?
22 What is supportive care?
23 Should a patient get a second opinion?
24 Many people are volunteering different opinions. How should I handle that?
25 How should I manage my emotions now that I have been diagnosed with biliary cancer?
26 What insurance and financial concerns does a patient need to address after a diagnosis of biliary cancer?
Part Five Treatment
39(62)
Questions 27-75 Focus on treatments available for biliary cancers, including
27 Which treatment options are available for intrahepatic cholangiocarcinoma?
28 What treatment options are available for extrahepatic bile duct cancers?
29 Which treatment options are available for gallbladder cancer?
30 What determines whether cholangiocarcinoma can be removed?
31 What determines whether my bile duct cancer can be removed by surgery?
32 What factors determine whether gallbladder cancer can be removed or not?
33 What is multidisciplinary care?
34 What preparations are made before a surgery?
35 What happens during a surgery?
36 How extensive is the surgery?
37 What happens in the hospital after surgery?
38 What are the risks of surgery for biliary cancer?
39 What is included in the pathology report from my surgery?
40 Will I be cured after a surgery?
41 What are neoadjuvant, adjuvant, and peri-adjuvant therapies?
42 Should I receive adjuvant chemotherapy and/or radiation therapy after surgery to prevent a recurrence of the tumor?
43 If the tumor cannot be surgically removed now, can I have chemotherapy first and then undergo surgery?
44 What happens if my biliary cancer returns?
45 Can liver transplantation be performed for cholangiocarcinoma?
46 Where do new livers for liver transplants come from?
47 What are the complications of liver transplantation?
48 What is tumor ablation, and can it be used for the treatment of cholangiocarcinoma?
49 What is hepatic artery embolization, and can it be used to treat cholangiocarcinoma?
50 What is radioembolization?
51 What are radiofrequency ablation and cryotherapy, and can they be used for the treatment of cholangiocarcinoma?
52 What is systemic therapy or chemotherapy?
53 Do I need to stay in the hospital to receive chemotherapy?
54 What are some of the general side effects of chemotherapy?
55 I am worried I may get nauseous or vomit. How are these symptoms prevented or treated?
56 The combination of gemcitabine plus cisplatin is a standard treatment for biliary cancers. How does this treatment plan work?
57 What is gemcitabine? And what are its side effects?
58 What is cisplatin? And what are its side effects?
59 How will I know that my treatment is working?
60 What kind of scan is best to assess a tumor response?
61 What are tumor markers?
62 If my cancer progresses on first-line therapy like gemcitabine and cisplatin, what should I do next?
63 What are FOLFOX and FOLFIRI therapies? And what are their side effects?
64 What are biological therapies? Are there any specific new biological drugs being tested for biliary cancers?
65 What are pemigatinib and infigratinib? And what are their side effects?
66 What about other targets and their therapies?
67 What is a clinical trial?
68 Where can I learn about clinical trials for biliary cancers, and how do I know which trial is best for me?
69 What is liver pump chemotherapy?
70 What is radiation therapy?
71 Can radiation be used for the treatment of biliary cancers?
72 Are there other uses for radiation?
73 What are complementary and alternative treatments? How do I decide whether I should use one of the complementary or alternative therapies that my family or friends are recommending?
74 What if my doctor recommends that no treatment should be performed?
75 How should I use the Internet to learn about my cancer? What about social media?
Part Six Cancer-Related Practical Issues
101(16)
Questions 76-83 Describe practical considerations for patients with biliary cancers, such as
76 I feel overwhelmed by all of the information that I am receiving. How do I make any decisions regarding my treatment?
77 Will changing my diet affect my cancer?
78 I am concerned I am losing weight. Can I do something about it?
79 I feel tired. What can I do to help with fatigue?
80 I am experiencing pain. How can I stop it?
81 How do I prevent or relieve nausea and/or vomiting?
82 I cannot sleep at night. What can I do to sleep better and feel more rested?
83 What is a mediport?
Part Seven Biliary Cancer-Specific Issues
117(8)
Question 84--89 Discuss issues specifically seen in biliary cancer, including
84 I have been told I have jaundice. Why are my eyes and/or skin yellow?
85 What is the difference between a stent and a drain?
86 How is a mechanical bile duct blockage fixed?
87 What are the risks associated with a biliary catheter and how do I care for it?
88 My abdomen and/or legs are swollen. What is edema? What is ascites?
89 How do you treat edema and ascites? What is a paracentesis?
Part Eight Family, Social, and End-of-Life Issues
125(12)
Questions 90-100 Explore key issues of managing family and social concerns, particularly end-of-life care, including
90 I feel depressed. How can I get help?
91 Can I work during treatment?
92 What if my doctors suggest stopping my current therapy?
93 What is palliative care?
94 What is hospice?
95 What are advance directives?
96 What is a healthcare proxy?
97 How can we prepare to die? Where can we find hope?
98 Where can I find additional information?
99 Should I still seek treatment for my biliary cancer even during the current COVID-19 pandemic?
100 Are there foundations that help or support patients with biliary cancers?
Glossary 137(8)
Resources 145(4)
Index 149
Ghassan K. Abou-Alfa, MD, is a member of the Gastrointestinal Oncology Service at Memorial Sloan-Kettering Cancer Center in New York, where he specializes in the treatment of primary liver cancer. Dr. Abou-Alfa received his medical degree from the American University of Beirut, Lebanon, and completed his post-doctoral training at Yale University School of Medicine. His research is dedicated to finding novel therapies and improving the effectiveness of current therapies for primary liver cancer, while continuing to understand the basic mechanisms of the disease and its therapies. Dr. Abou-Alfa also focuses on the study of prevention of recurrence of primary liver cancer after surgery and has many publications in the field of primary liver cancer. Dr. Abou-Alfa is a strong advocate for raising awareness about liver cancer and has lectured on the subject at universities worldwide.

Dr. Eileen M. OReilly is an Associate Member of the in the GI Medical Oncology service at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York and an Associate Professor of Medicine at Weill Medical College of Cornell University.'Dr. OReilly received her medical degree at Trinity College (Dublin University) in Ireland, where she was born.'She completed her residency training in Ireland and Fellowship training at MSKCC and has been a faculty member in the GI Oncology service at MSKCC since that time.'Dr. OReilly has pancreatic, biliary, neuroendocrine and primary liver cancers as the major focus of her clinical and research activities.'Research initiatives include integration of molecular-based therapies for the treatment of pancreas cancer along with development of adjvuant and neoadjuvant therapy.'At a national level, Dr. OReilly is a member of CALGBs GI committee and also participates in RTOG and ACOSOG.'Dr. OReillys insitutional administrative commitments include participation in MSKCCs IRB, Research Council and Clinical Council and Medical Board.'Dr. OReilly is also the current President of the MSKCC medical staff.